Tag: InspireMD

InspireMD Announces Presentation of Preliminary Cumulative Three-Year CGuard™ EPS Safety and Efficacy Data at the Transcatheter Cardiovascular Therapeutics 2018 Conference

TEL AVIV, Israel, Sept. 27, 2018 (GLOBE NEWSWIRE) — InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced that preliminary cumulative three-year follow-up safety, efficacy and stroke prevention durability data from […]

InspireMD Announces Regulatory Approval of CGuard™ Embolic Prevention System in Mexico

TEL AVIV, Israel, Sept. 24, 2018 (GLOBE NEWSWIRE) — InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced that its novel CGuard™ Embolic Prevention System (EPS) has been granted regulatory approval […]

InspireMD Announces Issuance of Two New U.S. Patents Covering Proprietary MicroNet™ Stent Jacket and Related Drug Eluting Technology

TEL AVIV, Israel, Sept. 17, 2018 (GLOBE NEWSWIRE) — InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced that the United States Patent and Trademark Office (USPTO) has issued US Patents […]

InspireMD to Present at the H.C. Wainwright 20th Annual Global Investment Conference in New York City

TEL AVIV, ISRAEL, Sept. 04, 2018 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE – InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced it will be presenting at the H.C. Wainwright 20th Annual […]

InspireMD Reports 94% Increase in CGuard™ EPS Revenues for the Second Quarter of 2018

TEL AVIV, Israel, Aug. 06, 2018 (GLOBE NEWSWIRE) — InspireMD, Inc. (NYSE American:NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced results for the second quarter ending June 30, 2018. Second Quarter 2018 highlights: Revenues […]

InspireMD, Inc. Announces Pricing of $10 Million Underwritten Public Offering

Tel Aviv, Israel, June 29, 2018 (GLOBE NEWSWIRE) — InspireMD, Inc. (NYSE American: NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced the pricing of an underwritten public offering of 33,333,333 units at a price to the public of $0.30 per unit. InspireMD expects […]

InspireMD’s CGuard EPS Featured at the SBHCI Congress in Brazil

Tel Aviv, Israel, June 20, 2018 (GLOBE NEWSWIRE) — InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced that CGuard™ EPS was featured at the SBHCI Congress, sponsored by the Brazilian Society of Hemodynamics and Interventional Cardiology, which took […]

InspireMD’s CGuard EPS Prominently Featured at the 10th International Congress of the Polish Society for Vascular Surgery

Tel Aviv, Israel, June 18, 2018 (GLOBE NEWSWIRE) — InspireMD, Inc. (NYSE AMER: NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced that study results on its CGuard™ EPS were presented at the 10th International Congress of the Polish Society for Vascular Surgery […]